Artelo Biosciences (ARTL) announced it has commenced an underwritten public offering of its common stock and/or pre-funded warrants. All shares of common stock and/or pre-funded warrants in the offering are to be offered by the company. R.F. Lafferty & Co., Inc. is acting as the sole book-running manager for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo does not envision need to internally fund Phase 3 trial of ART27.13
- Artelo Biosciences announces interim Phase 2 CAReS results
- Artelo Biosciences Approves Common Stock Increase
- Artelo Biosciences announces data on food effect evaluation with ART26.12
- Artelo Biosciences Ends Securities Purchase Agreement